[Pharmcodynamic evaluation of the use of anaprilin combined with merkazolil for the therapy of thyrotoxicosis].
Anaprilin pharmacodynamics was studied in thyrotoxicosis patients. The clinical therapeutic effect of anaprilin, mercazolyl and their combinations was studied. In anaprilin therapy the drug should be individually dosed out with regard to its basal concentration in the blood and the degree of pulse retardation at rest. An adequate anaprilin dose for most patients was 160 mg/day. Anaprilin-mercazolyl combined therapy resulted in more retarded pulse as compared to a single drug therapy with anaprilin. The effect of anaprilin was potentiated by mercazolyl doses which did not by themselves cause a positive cardiovascular effect in the first two weeks of therapy.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006111:Graves Disease / Q000188:drug therapy / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000503:physiopathology; D007700:Kinetics; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged; D011433:Propranolol / Q000097:blood / Q000627:therapeutic use*; D013997:Time Factors
D008713:Methimazole; D011433:Propranolol
Farmakodinamicheskaia otsenka primeneniia anaprilina v sochetanii s merkazolilom dlia terapii tireotoksikoza.